White House Orders $50 Million Push to Fast-Track Psychedelic Treatments for Mental Illness

The White House announced a presidential action on April 18, 2026, directing federal health agencies to speed up research and regulatory approval of psychedelic-based treatments for serious mental illness.

The order instructs the Secretary of Health and Human Services to allocate at least $50 million from existing funds through the Advanced Research Projects Agency for Health. The money will support state governments developing programs that use psychedelic compounds, including ibogaine, for conditions such as major depressive disorder and substance abuse disorders.

The FDA and the Drug Enforcement Administration are directed to prioritize review of these substances and facilitate access under the Right to Try Act.

The action follows years of growing research interest in psychedelics as potential treatments for mental health conditions that have not responded well to traditional medications. Clinical trials at universities including Johns Hopkins and NYU have shown promising results for psilocybin and MDMA in treating depression and PTSD.

Mental health advocates welcomed the announcement. The American Psychiatric Association has noted that 38% of Americans plan to make mental health-related resolutions in 2026, a 5% increase from the previous year.

Zurich Insurance Group released a report on April 29 warning that unaddressed mental health issues could cost up to 5% of global GDP by 2030. The report said early intervention, including rehabilitation services, can help about one-third of affected employees stay in the workforce.

Critics of the psychedelic treatment push have raised concerns about safety, the potential for misuse, and the need for more long-term data before widespread clinical adoption.

The administration said the initiative is part of a broader effort to address what officials described as a mental health crisis affecting millions of Americans.